Search clinical trials for: Macugen

Total 41 results

Kagawa University

Recruiting

Cohort Study of the Clinical Course of Macular Diseases in Kagawa

Macular Disease

Japan
Elevar Therapeutics

Terminated

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Wake Forest University

Completed

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

Uveitis | Cystoid Macular Edema

United States
Bausch & Lomb Incorporated

Completed

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Age-Related Macular Degeneration | Diabetic Macular Edema | Retinal Vein Occlusion

United States
Pfizer

Completed

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life. (MACURELI)

Neovascular Age-related Macular Degeneration

Belgium
Pfizer

Completed

Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice

Age-related Macular Degeneration

Czechia
Pfizer

Completed

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

Macular Edema Associated With Diabetes Mellitus

United States, Colombia, Australia, Germany, Italy, South Africa, Greece, France, Austria, United Kingdom, Denmark, India, Portugal, Brazil, Canada, Czechia, Netherlands, Switzerland
Novartis Pharmaceuticals
QLT Inc.

Completed

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib (VERITAS)

Macular Degeneration | Choroidal Neovascularization

United States
Pfizer

Completed

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Macular Degeneration
L.V. Prasad Eye Institute
Pfizer

Withdrawn

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia (INGECT)

Myopic Choroidal Neovascular Membrane

India
Association for Innovation and Biomedical Research...

Completed

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Diabetes Mellitus Type II | Diabetes Mellitus Type I | High Risk Proliferative Diabetic Retinopathy

Portugal
Pfizer

Withdrawn

Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

Neovascular Age-related Macular Degeneration
University of Oxford
Pfizer

Completed

Intravitreal Macugen for Ischaemic Diabetic Macular Oedema (MIDME)

Diabetic Macular Oedema

United Kingdom
Palmetto Retina Center, LLC
Pfizer; Eyetech Pharmaceuticals

Completed

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion

United States
Greater Houston Retina Research

Withdrawn

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy (No-Crunch01)

Proliferative Diabetic Retinopathy

United States
Pfizer

Completed

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Macular Edema | Retinal Disease | Diabetic Mellitus

Japan
Valley Retina Institute

Completed

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study (PRESERVE)

Diabetic Macular Edema

United States
Pfizer

Completed

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Macular Degeneration

Greece, Italy, Slovakia, Spain, Sweden, Czech Republic, Germany, Belgium, France, Cyprus, Denmark, Ireland, Poland
Retina Institute of Hawaii

Completed

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD

United States
Lawson Health Research Institute
Pfizer

Completed

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema) (PEGAP001)

Diabetic Macular Edema | Proliferative Diabetic Retinopathy

Canada
Pfizer

Completed

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice. (MACULA)

Neovascular Age-related Macular Degeneration

Greece
Pfizer

Terminated

An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD (PERSPECTIVES)

Macular Degeneration | Age Related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV)

Canada, Belgium, United Kingdom, France, Poland, Spain, Turkey, Czech Republic, Italy, Greece, Germany, Austria, Portugal, Denmark, Finland
Retina Institute of Hawaii
Eyetech Pharmaceuticals

Available

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema (GUARDIAN)

Diabetic Macular Edema

United States
Retina Institute of Hawaii

Completed

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

PDR

United States
Valley Retina Institute
Pfizer

Unknown

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Proliferative Diabetic Retinopathy

United States
Klinikum Ludwigshafen
Pfizer

Unknown

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

Age-related Macular Degeneration

Germany
Pfizer

Terminated

Macugen Observational Study

Macular Degeneration | Vascular Endothelial Growth Factor

India
Pfizer

Completed

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration (MACULA)

Macular Degeneration | Age-related Macular Degeneration | Neovascular Macular Degeneration
Pfizer
ITEC GROUP 3

Completed

Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions

Macular Degeneration

France
The Ludwig Boltzmann Institute of Retinology and...

Completed

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

Macular Degeneration

Austria
Hermann Eye Center
Eyetech Pharmaceuticals

Completed

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

Diabetic Retinopathy | Iris Neovascularization

United States
Johns Hopkins University
Eyetech Pharmaceuticals

Terminated

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

Cystoid Macular Edema

United States
Johns Hopkins University
Eyetech Pharmaceuticals

Terminated

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

Cystoid Macular Edema

United States
Eyetech Pharmaceuticals
Pfizer

Terminated

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration

United States
Eyetech Pharmaceuticals
Pfizer

Unknown

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Age-Related Macular Degeneration (AMD)

United States
Eyetech Pharmaceuticals
Pfizer

Terminated

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Barnes Retina Institute
Pfizer

Terminated

Macugen for Histoplasmosis

Choroidal Neovascularization | Ocular Histoplasmosis

United States
Eyetech Pharmaceuticals
Pfizer

Completed

A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.

Age-Related Macular Degeneration
Eyetech Pharmaceuticals
Pfizer

Completed

Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)

Macular Degeneration
Eyetech Pharmaceuticals
Pfizer

Completed

Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)

Age-Related Macular Degeneration
Eyetech Pharmaceuticals

Completed

Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula

Diabetic Macular Edema

3

Subscribe